Advertisement

Molecular Medicine

, Volume 21, Supplement 1, pp S25–S31 | Cite as

Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer—20 Years of Progress

  • Jennifer E. Hardingham
  • Phulwinder Grover
  • Marnie Winter
  • Peter J. Hewett
  • Timothy J. Price
  • Benjamin Thierry
Invited Review Article

Abstract

Circulating tumor cells (CTC) may be defined as tumor- or metastasis-derived cells that are present in the bloodstream. The CTC pool in colorectal cancer (CRC) patients may include not only epithelial tumor cells, but also tumor cells undergoing epithelial-mesenchymal transition (EMT) and tumor stem cells. A significant number of patients diagnosed with early stage CRC subsequently relapse with recurrent or metastatic disease despite undergoing “curative” resection of their primary tumor. This suggests that an occult metastatic disease process was already underway, with viable tumor cells being shed from the primary tumor site, at least some of which have proliferative and metastatic potential and the ability to survive in the bloodstream. Such tumor cells are considered to be responsible for disease relapse in these patients. Their detection in peripheral blood at the time of diagnosis or after resection of the primary tumor may identify those early-stage patients who are at risk of developing recurrent or metastatic disease and who would benefit from adjuvant therapy. CTC may also be a useful adjunct to radiological assessment of tumor response to therapy. Over the last 20 years many approaches have been developed for the isolation and characterization of CTC. However, none of these methods can be considered the gold standard for detection of the entire pool of CTC. Recently our group has developed novel unbiased inertial microfluidics to enrich for CTC, followed by identification of CTC by imaging flow cytometry. Here, we provide a review of progress on CTC detection and clinical significance over the last 20 years.

Notes

Acknowledgments

This work was supported by grants from the National Health and Medical Research Council Australia (project grant APP1045841), Cancer Council of South Australia, and the Hospital Research Foundation.

References

  1. 1.
    Australian Institute of Health and Welfare (AIHW). (2014) Cancer in Australia: an overview 2014. Canberra: AIHW. Cancer series No. 90.Google Scholar
  2. 2.
    Siegel R, DeSantis C, Jemal A. (2014) Colorectal cancer statistics, 2014. CA Cancer J. Clin. 64:104–117.CrossRefGoogle Scholar
  3. 3.
    Klein C. (2009) Parallel progression of primary tumours and metastases. Nat. Rev. Cancer. 9:302–312.CrossRefGoogle Scholar
  4. 4.
    Hardingham JE, et al. (1995) Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Mol. Med. 1:789–794.CrossRefGoogle Scholar
  5. 5.
    Tsavellas G, Patel H, Allen-Mersh TG. (2001) Detection and clinical significance of occult tumour cells in colorectal cancer. Br. J. Surg. 88:1307–1320.CrossRefGoogle Scholar
  6. 6.
    Hardingham JE, et al. (2000) Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int. J. Cancer 89:8–13.CrossRefGoogle Scholar
  7. 7.
    Sergeant G, Penninckx F, Topal B. (2008) Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood-a systematic review. J. Surg. Res. 150:144–152.CrossRefGoogle Scholar
  8. 8.
    Torino F, et al. (2013) Circulating tumor cells in colorectal cancer patients. Cancer Treat. Rev. 39:759–772.CrossRefGoogle Scholar
  9. 9.
    Alix-Panabieres C, Pantel K. (2014) Technologies for detection of circulating tumor cells: facts and vision. Lab Chip. 14:57–62.CrossRefGoogle Scholar
  10. 10.
    Cole SR, et al. (2013) Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med. J. Aust. 198:327–330.CrossRefGoogle Scholar
  11. 11.
    Roder D, et al. (2015) Colorectal cancer treatment and survival: the experience of major public hospitals in South Australia over three decades. Asian Pac. J. Cancer Prev. 16:2431–2440.CrossRefGoogle Scholar
  12. 12.
    Bagshaw PF, et al. (2012) Long-term outcomes of the australasian randomized clinical trial comparing laparoscopic and conventional open surgical treatments for colon cancer: the Australasian Laparoscopic Colon Cancer Study trial. Ann. Surg. 256:915–919.CrossRefGoogle Scholar
  13. 13.
    Lloyd JM, et al. (2006) Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin. Cancer Res. 12:417–423.CrossRefGoogle Scholar
  14. 14.
    Gray R, et al. (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 370:2020–2029.CrossRefGoogle Scholar
  15. 15.
    Pantel K, Brakenhoff RH, Brandt B. (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer. 8:329–340.CrossRefGoogle Scholar
  16. 16.
    Hardingham JE, et al. (1993) Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res. 53:3455–3458.PubMedGoogle Scholar
  17. 17.
    Cristofanilli M, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl. J. Med. 351:781–791.CrossRefGoogle Scholar
  18. 18.
    Riethdorf S, et al. (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13:920–928.CrossRefGoogle Scholar
  19. 19.
    Cohen SJ, et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:3213–3221.CrossRefGoogle Scholar
  20. 20.
    de Bono JS, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14:6302–6309.CrossRefGoogle Scholar
  21. 21.
    Rahbari NN, et al. (2010) Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 138:1714–1726.e1713.CrossRefGoogle Scholar
  22. 22.
    Groot Koerkamp B, Rahbari N, Büer M, Koch M, Weitz J. (2013) Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann. Surg. Oncol. 20:2156–2165.CrossRefGoogle Scholar
  23. 23.
    Pantel K, et al. (2012) Circulating epithelial cells in patients with benign colon diseases. Clin. Chem. 58:936–940.CrossRefGoogle Scholar
  24. 24.
    Beije N, Jager A, Sleijfer S. (2015) Circulating tumor cell enumeration by the CellSearch system: the clinician’s guide to breast cancer treatment? Cancer Treat. Rev. 41:144–150.CrossRefGoogle Scholar
  25. 25.
    Lu CY, et al. (2013) Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br. J. Cancer. 108:791–797.CrossRefGoogle Scholar
  26. 26.
    Krebs MG, et al. (2015) Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer. Clin. Colorectal Cancer. 14:115–122.CrossRefGoogle Scholar
  27. 27.
    Bork U, et al. (2015) Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br. J. Cancer. 112:1306–1313.CrossRefGoogle Scholar
  28. 28.
    Paterlini-Brechot P, Benali NL. (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 253:180–204.CrossRefGoogle Scholar
  29. 29.
    Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. (2010) Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther. Adv. Med. Oncol. 2:351–365.CrossRefGoogle Scholar
  30. 30.
    Tol J, et al. (2010) Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol. 21:1006–1012.CrossRefGoogle Scholar
  31. 31.
    Rao CG, et al. (2005) Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int. J. Oncol. 27:49–57.PubMedGoogle Scholar
  32. 32.
    Gervasoni A, et al. (2011) Comparison of three distinct methods for the detection of circulating tumor cells in colorectal cancer patients. Oncol. Rep. 25:1669–1703.PubMedGoogle Scholar
  33. 33.
    Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE. (2014) Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann. Oncol. 25:1506–1516.CrossRefGoogle Scholar
  34. 34.
    Thurm H, et al. (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin. Cancer Res. 9:2598–2604.PubMedGoogle Scholar
  35. 35.
    Gorges T, et al. (2012) Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 12:178.CrossRefGoogle Scholar
  36. 36.
    Labelle M, Begum S, Hynes RO. (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 20:576–590.CrossRefGoogle Scholar
  37. 37.
    Polyak K, Weinberg RA. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer. 9:265–273.CrossRefGoogle Scholar
  38. 38.
    Bednarz-Knoll N, Alix-Panabières C, Pantel K. (2012) Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 31:673–687.CrossRefGoogle Scholar
  39. 39.
    Mani SA, et al. (2008) The epithelial-mesenchymal S31 transition generates cells with properties of stem cells. Cell. 133:704–715.CrossRefGoogle Scholar
  40. 40.
    Mitra A, Mishra L, Li S. (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 6:10697–10711.CrossRefGoogle Scholar
  41. 41.
    Wicha MS, Hayes DF. (2011) Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol. 29:1508–1511.CrossRefGoogle Scholar
  42. 42.
    van de Stolpe A, Pantel K, Sleijfer S, Terstappen LW, den Toonder JMJ. (2011) Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res. 71:5955–5960.CrossRefGoogle Scholar
  43. 43.
    Paterlini-Bréchot P. (2014) Circulating tumor cells: who is the killer? Cancer Microenviron. 7:161–176.CrossRefGoogle Scholar
  44. 44.
    Pang R, et al. (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 6:603–615.CrossRefGoogle Scholar
  45. 45.
    Iinuma H, et al. (2011) Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J. Clin. Oncol. 29:1547–1555.CrossRefGoogle Scholar
  46. 46.
    Valladares-Ayerbes M, et al. (2012) Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as bio-markers in colorectal cancer. Int. J. Mol. Sci. 13:4367–4387.CrossRefGoogle Scholar
  47. 47.
    Han Y, et al. (2015) LGR5, a relevant marker of cancer stem cells, indicates a poor prognosis in colorectal cancer patients: a meta-analysis. Clin. Res. Hepatol. Gastroenterol. 39:267–273.CrossRefGoogle Scholar
  48. 48.
    Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. (2002) VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood. 101:168–172.CrossRefGoogle Scholar
  49. 49.
    Koo B-K, Clevers H. (2014) Stem cells marked by the R-spondin receptor LGR5. Gastroenterology. 147:289–302.CrossRefGoogle Scholar
  50. 50.
    Grover PK, Hardingham JE, Cummins AG. (2010) Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev. 29:761–775.CrossRefGoogle Scholar
  51. 51.
    van der Flier LG, Haegebarth A, Stange DE, van de Wetering M, Clevers H. (2009) OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology. 137:15–17.CrossRefGoogle Scholar
  52. 52.
    Barker N, et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 449:1003–1007.CrossRefGoogle Scholar
  53. 53.
    Sato T, et al. (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 141:1762–1772.CrossRefGoogle Scholar
  54. 54.
    Yokobori T, et al. (2013) Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 73:2059–2069.CrossRefGoogle Scholar
  55. 55.
    Sanders MA, Majumdar APN. (2011) Colon cancer stem cells: implications in carcinogenesis. Front. Biosci. 16:1651–1662.CrossRefGoogle Scholar
  56. 56.
    Gao W, et al. (2013) Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology. 145:636–646.e5.CrossRefGoogle Scholar
  57. 57.
    Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M. (2014) Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One. 9:e94621.CrossRefGoogle Scholar
  58. 58.
    Kantara C, et al. (2015) Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis. Lab. Invest. 95:100–112.CrossRefGoogle Scholar
  59. 59.
    Harouaka R, Kang Z, Zheng S, Cao L. (2014) Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol. Ther. 141:209–221.CrossRefGoogle Scholar
  60. 60.
    Alix-Panabieres C, Pantel K. (2014) Challenges in circulating tumour cell research. Nat. Rev. Cancer. 14:623–631.CrossRefGoogle Scholar
  61. 61.
    Low WS, Wan Abas WA. (2015) Benchtop technologies for circulating tumor cells separation based on biophysical properties. Biomed Res. Int. 2015:239362.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Wang L, Asghar W, Demirci U, Wan Y. (2013) Nanostructured substrates for isolation of circulating tumor cells. Nano Today. 8:347–387.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Chen W, et al. (2013) Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies. ACS Nano. 7:566–575.CrossRefGoogle Scholar
  64. 64.
    Wan Y, et al. (2014) Nanostructured polystyrene well plates allow unbiased high-throughput characterization of circulating tumor cells. ACS Appl. Mater. Interfaces. 6:20828–20836.CrossRefGoogle Scholar
  65. 65.
    Goda K, et al. (2012) High-throughput single-microparticle imaging flow analyzer. Proc. Natl. Acad. Sci. U. S. A. 109:11630–11635.CrossRefGoogle Scholar
  66. 66.
    Reyes EE, et al. (2014) Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J. Transl. Med. 12:313.CrossRefGoogle Scholar
  67. 67.
    Warkiani ME, et al. (2014) Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab Chip. 14:128–137.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Jennifer E. Hardingham
    • 1
    • 2
    • 3
  • Phulwinder Grover
    • 4
  • Marnie Winter
    • 5
  • Peter J. Hewett
    • 4
  • Timothy J. Price
    • 2
    • 6
  • Benjamin Thierry
    • 5
  1. 1.Molecular Oncology Group, Haematology-Oncology Department, Level 1The Basil Hetzel Institute, The Queen Elizabeth HospitalWoodvilleAustralia
  2. 2.School of MedicineUniversity of AdelaideAdelaideAustralia
  3. 3.Centre for Personalized MedicineUniversity of AdelaideAdelaideAustralia
  4. 4.Department of SurgeryThe Queen Elizabeth HospitalWoodvilleAustralia
  5. 5.Ian Wark Research InstituteUniversity of South AustraliaMawson LakesAustralia
  6. 6.Medical OncologyThe Queen Elizabeth HospitalWoodvilleAustralia

Personalised recommendations